试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-09-21
Dosing Strategies for Automated Mandatory Intermittent Boluses Technique for Epidural Labour Analgesia
编号:NCT01205360登记状态:入组前撤回企业 / 申办者:Pravara Institute of Medical Sciences University
药物 / 成分:Bupivacaine-Fentanyl Mixture、Bupivacaine-Fentanyl Mixture、Bupivacaine-Fentanyl Mixture
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-09-21
Clinical Trial With Combination of Dienogest/Ethytnilestradiol and Drosperidona/Ethyniestradiol
编号:NCT01557023登记状态:入组前撤回企业 / 申办者:Eurofarma Laboratorios S.A.
药物 / 成分:barrier methods、barrier methods
登记的停止原因(原文):Change Company strategy
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-09-21
Efficacy of Remodulin in Adults With Congenital Heart Disease (ACHD) and Pulmonary Hypertension
编号:NCT01980979登记状态:入组前撤回企业 / 申办者:University of California, Los Angeles
药物 / 成分:Remodulin
登记的停止原因(原文):slow enrollment
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-09-20
Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone
编号:NCT02736123登记状态:入组前撤回企业 / 申办者:University of Pittsburgh
药物 / 成分:Nivolumab - Arm A、Nivolumab + Ipilimumab - Arm B
登记的停止原因(原文):PI is closing the trial as he will be leaving the University of Pittsburgh Medical Center
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-09-20
Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma
编号:NCT03283046登记状态:入组前撤回企业 / 申办者:M.D. Anderson Cancer Center
药物 / 成分:Nivolumab、Lenalidomide、Dexamethasone、Ipilimumab
登记的停止原因(原文):Similar to another study.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-09-19
Temozolomide and Topotecan in Treating Patients With Primary CNS Lymphoma
编号:NCT00109798登记状态:入组前撤回企业 / 申办者:The Methodist Hospital Research Institute
药物 / 成分:temozolomide、topotecan hydrochloride
登记的停止原因(原文):Sub-Investigator reloacted to another institution
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-09-19
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study
编号:NCT00837174登记状态:入组前撤回企业 / 申办者:The Methodist Hospital Research Institute
药物 / 成分:Vorinostat in combination with Bortezomib
登记的停止原因(原文):Study never activated/opened as funding source and other support not available.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-09-19
Phase II Trial of Chemotherapy With Temodar With Topotecan for CNS Metastasis of Solid Tumors
编号:NCT01736800登记状态:入组前撤回企业 / 申办者:The Methodist Hospital Research Institute
药物 / 成分:Topotecan、Temozolomide
登记的停止原因(原文):No enrollment and PI requested study termination per IRB system.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-09-18
LDX for the Treatment of Cognitive Functioning Issues in Women Post-Oophorectomy
编号:NCT01986777登记状态:入组前撤回企业 / 申办者:University of Pennsylvania
药物 / 成分:lisdexamfetamine、Placebo
登记的停止原因(原文):Funding not obtained
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-09-15
Trial to Compare the Efficacy and Safety of Pegfilgrastim Biosimilar in Subjects With High Risk Stage Breast Cancer Receiving Chemotherapy
编号:NCT02768714登记状态:入组前撤回企业 / 申办者:Eurofarma Laboratorios S.A.
药物 / 成分:Eurofarma's pegfilgrastim、Neulastim
登记的停止原因(原文):Strategic changes regarding the product development
查看官方原始记录 ↗